GLAVINE PAUL (Chief Growth Officer) purchased 2.5% of their position (100K shares) of HELUS PHARMA INC. on the open market
Open‑market purchase worth $1.18M — a small addition. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 9/10/2026ACC: 0000912282-26-001256
Officer· Chief Growth Officer
Since Aug 2026
+100K
Net shares
Net buyer
$1.18M
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
100K acquired
Non-Derivative Transactions1
Common Shares
Direct
Shares
+100K
Price / share
$11.78
Trade value
$1.18M
% of position
2.5%
9/3/2026
4.07M→4.17M
Total
Net shares
+100K
Net value
$1.18M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 9/3/2026 | P · Purchase | +100K | $11.78 | $1.18M | 2.5% | 4.07M | 4.17M |
| Total | +100K | $1.18M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Shares
IndirectShares owned230.94K
Total
230.94K indirect230.94K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 230.94K | Indirect |
| Total | 230.94K | 230.94K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported